QMS Medical Allied Services Limited (NSE: QMSMEDI), a leading integrated healthcare solutions company, today announced the signing of an exclusive five-year agreement with HEINE Optotechnik, a globally reputed primary diagnostic instruments company. The agreement, which was signed at the HEINE headquarters in Gilching, Germany, designates QMS as the sole distributor in India for HEINE’s wide range of diagnostic instruments starting from 1st January 2027. This partnership is expected to significantly boost QMS’s product business, leveraging its pan-India distribution capabilities.

Exclusive Marketing and Distribution Rights

Under the agreement, QMS will be the exclusive distributor for HEINE Optotechnik’s products across India for the next five years. The contract includes General Medicine and ENT-Instruments, Dermatoscopes, Ophthalmic Instruments, Laryngoscopes, Loupes, Headlights, Veterinary Diagnostic Instruments, Power Sources, Bulbs, Cases, Spare parts, and special products. HEINE shall not appoint or supply any other distributor for these products in India.

Expected Growth and Market Impact

HEINE’s net revenues from India for 2026 are expected to be around 2.6 million Euros (~Rs. 30 crore). The partnership is anticipated to increase QMS’s turnover to Rs. 70 crore by 2031. This agreement aligns with QMS’s strategy to expand its product business and accelerate its growth trajectory over the next five years.

Commenting on the agreement, Mr. Mahesh Makhija, Chairman & Managing Director of QMS Medical Allied Services Limited, said, “We are thrilled to welcome HEINE Optotechnik to the QMS family. The exclusive partnership is central to our product business expansion strategy and will help us accelerate our growth trajectory over the next five years. Besides, this collaboration will open more doors for the company to capitalize on its wider presence and established reputation in a fast-growing Indian healthcare space.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.

QMS Medical Allied Services Ltd (NSE: QMSMEDI) has reported its Q1FY27 results, marking a strong start to the fiscal year. The company delivered a revenue of Rs. 56.9 crore, reflecting a 22% year-on-year growth. EBITDA increased by 27% to Rs. 8.3 crore, with margins improving to 14.6%. Profit after tax (PAT) stood at Rs. 4 crore, representing a 25% YoY growth.

Revenue and Profit Growth

The company’s Products business continued to demonstrate healthy traction, supported by its expanding distribution network and the Q-Devices portfolio. The Services business emerged as a key growth engine, driven by deeper pharma partnerships and increasing adoption of Patient Support Programs. The company expects to acquire the remaining stake in Saarathi Healthcare by the end of Q2FY27, further strengthening its capabilities in disease management and Patient Support Programs.

Financial Highlights

The consolidated revenue from operations for Q1FY27 was Rs. 56.9 crore, compared to Rs. 46.5 crore in Q1FY26. EBITDA increased to Rs. 8.3 crore, up from Rs. 6.5 crore in the same period last year. PAT grew to Rs. 4 crore, up from Rs. 3.2 crore. The company remains confident in its growing capabilities, strong customer relationships, and expanding presence across the healthcare ecosystem, positioning QMS for sustainable growth and long-term value creation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.

QMS Medical Allied Services Ltd has reported strong financial results for Q1FY27, reflecting the strength of its integrated healthcare business model and the investments made over the past year. The company delivered revenue of Rs. 56.9 crore, growing 22% YoY, while PAT stood at Rs. 4 crore, representing a 25% YoY growth. EBITDA increased 27% YoY to Rs. 8.3 crore, with EBITDA margins improving to 14.6%.

Product and Service Segments

Our Products business continued to demonstrate healthy traction, supported by our expanding distribution network, Q-Devices portfolio, and presence across QMSMEDS, e-Grameen, and other digital platforms. At the same time, our Services business continued to emerge as a key growth engine, driven by deeper pharma partnerships, increasing adoption of Patient Support Programs, and the scaling of our healthcare camp operations.

Strategic Initiatives

We currently hold a 76% stake in Saarathi Healthcare and expect to acquire the balance stake by the end of Q2FY27. This will further strengthen our capabilities in disease management and Patient Support Programs, enabling us to address the entire patient journey more comprehensively. As we move forward, our focus remains on scaling Patient Support Programs, strengthening strategic partnerships, expanding Q-Devices and Point-of-Care offerings, and leveraging our technology platform to deliver more integrated and scalable healthcare solutions.

We remain confident that our growing capabilities, strong customer relationships, and expanding presence across the healthcare ecosystem position QMS well for sustainable growth and long-term value creation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of QMS Medical Allied Services Limited

QMS Medical Allied Services Limited. Here’s a quick read on where the business and the stock stand today.

Symbol QMSMEDI not found in TradeAlone database.